ERBB2 and breast carcinoma: Blockade of HER2 signaling is one of the key elements for improving the clinical outcome in HER2+ breast cancers, and several trials have investigated the efficacy of various combination of HER2-targeted drugs in addition to conventional chemotherapies6.